UK pilots shorter NICE appraisal for new medicines

The UK's NHS and NICE have launched the SMART pilot program to accelerate patient access to promising new medicines. The initiative aims to reduce the initial assessment time from one year to six months by using a streamlined process followed by a full evaluation once more real-world evidence is gathered.
Why it matters
This pilot could significantly improve patient outcomes by providing faster access to life-saving treatments while maintaining rigorous long-term safety and financial standards.
UK reimbursement authority NICE and NHS England have launched a pilot of a shorter initial assessment process for promising new medicines that aims to slash the time it takes for them to reach patients from around a year to six months.
The SMART (Streamlined Managed Access Route for Therapies) pilot is one of a series of schemes designed to speed up and improve the fairness of how new treatments reach patients – first announced in July – that were drawn up in a 10-week 'sprint' process, with input from patient organisations.
For a medicine to be considered eligible for SMART, it must have highly promising early data, be capable of being introduced into the NHS quickly, have clear, robust plans in place to generate real-world evidence thereafter, and represent good value for money for the health service.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in